Rilzabrutinib - Principia Biopharma
Alternative Names: PRN 1008; SAR-444671Latest Information Update: 18 Jun 2025
At a glance
- Originator Principia Biopharma
- Developer Principia Biopharma; Sanofi
- Class 2 ring heterocyclic compounds; Amines; Anti-inflammatories; Antianaemics; Antiasthmatics; Fluorobenzenes; Nitriles; Phenyl ethers; Piperazines; Piperidines; Pyrazoles; Pyrimidines; Skin disorder therapies; Small molecules
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Idiopathic thrombocytopenic purpura
- Phase III Sickle cell anaemia
- Phase II Asthma; Autoimmune haemolytic anaemia; Chronic urticaria; Immunoglobulin G4-related disease
- No development reported Liver disorders
- Discontinued Atopic dermatitis; Pemphigus; Pemphigus vulgaris
Most Recent Events
- 12 Jun 2025 Efficacy and adverse events data from a phase IIa trial in Immunoglobulin G4 related disease released by Sanofi
- 06 Jun 2025 Sanofi plans a phase III LUNA 4 trial for Idiopathic thrombocytopenic purpura in Unknown location (PO, Tablet) in July 2025 (NCT07007962)
- 03 Jun 2025 Preregistration for Idiopathic thrombocytopenic purpura in China (PO)